Recent work in both animal and human subjects has implicated limbic-based circuitry, centered on the amygdala, in the generation and regulation of normal fearful responses as well as pathological anxiety (Damasio 1994; LeDoux 1997) . Likewise, amphetamine and other dopaminergic psychostimulants have been shown to produce pronounced effects on emotional behavior, including the generation of fear and anxiety (Angrist and Gershon 1970; Ellinwood et al. 1973; Hall et al. 1988) . Studies in animals suggest that such anxiogenic effects may reflect dopamine (DA) augmentation of amygdala activity (Willick and Kokkinidis 1995; Harmer et al. 1997; Harmer and Phillips 1999a,b; Rosenkranz and Grace 1999 . These convergent findings lead to the intriguing possibility that the emotion enhancing properties of amphetamine may be related to effects on the amygdala. We used dextroamphetamine (DEX), a potent monoaminergic agonist and anxiogenic, in a double-blind placebo controlled functional magnetic resonance imaging (fMRI) study to explore this possibility in human subjects.
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METHODS
Twelve healthy subjects (five males and seven females, mean age ϭ 33 years) gave written informed consent according to the guidelines of the National Institute of Mental Health Institutional Review Board. Each subject participated in two fMRI sessions, separated by three to ten days, with all conditions kept constant across sessions. Approximately 120 min before each session, subjects received an oral dose of either placebo (PBO) or DEX (0.25 mg/kg body weight) in a double-blind manner. The order of drug administration was counterbalanced across subjects by the pharmacy. Blood was drawn at the beginning of each session and serum DEX levels were measured using gas chromatography.
During each session, subjects completed a blocked fMRI paradigm consisting of two tasks. Subject performance (accuracy and reaction time) was monitored during all scans. In an emotion task, subjects were required to match the expression (either angry or afraid) of one of two faces to that of a simultaneously presented target face (Figure 1, panel A) . These stimuli were employed because previous neuroimaging studies have revealed that facial expressions, especially those of negative affect, elicit a robust amygdala response (Davis and Whalen 2001) . As a sensorimotor control task, subjects were required to match one of two geometric shapes with a simultaneously presented target shape (Figure 1, panel B) . We employed simple geometric shapes and not neutral facial expressions as control stimuli because subjects may perceive such "neutral" faces ambiguously and thus elicit an amygdala response (Thomas et al. 2001) . Thus, by contrasting matching of affective facial expressions with matching of simple geometric shapes we sought to maximize our ability to consistently and reliably engage the amygdala.
Blood oxygenation-level dependent (BOLD) fMRI was conducted on a GE Signa 3T scanner (Milwaukee, WI) with a gradient echo EPI sequence, covering 24 axial slices (4 mm thick, 1 mm gap), beginning at the cerebral vertex and encompassing the entire cerebrum and the majority of the cerebellum (TR/TE ϭ 2000/28 msec, FOV ϭ 24 cm, matrix ϭ 64 ϫ 64). Whole-brain image analysis was completed using SPM99 (http:// www.fil.ion.ucl.ac.uk/spm). Images for each subject were realigned to the first volume in the time series to correct for head motion, spatially normalized into a standard stereotactic space (Montreal Neurological Institute template) using a 12 parameter affine model and smoothed to minimize noise and residual differences in gyral anatomy with a Gaussian filter, set at 8 mm fullwidth at half-maximum. Voxel-wise signal intensities were ratio normalized to the whole-brain global mean. Predetermined condition effects at each voxel were calculated using a t-statistic, producing a statistical image for the contrast of the emotion task versus the sensorimotor control for each subject. These individual contrast images were then used in second-level random effects models, that account for both scan-to-scan and subject-to-subject variability, to determine task-specific regional responses at the group-level with one sample (main effects of task) and paired t -tests (DEX vs. PBO). A statistical threshold of p Ͻ .05, corrected for multiple comparisons based on the volumes of the regions of interest such as the amygdala, was used to identify significant responses for all comparisons (Worsley et al. 1996) . Table 1 provides a summary of brain regions that exhibited a significant BOLD fMRI response for all comparisons. Consistent with previous findings (Hariri et al. 2000) , there was a strong bilateral amygdala response during the perceptual processing of facial expressions in comparison to the sensorimotor control for both PBO and DEX sessions (Figure 2 ). Direct comparison of the two sessions revealed a DEX induced significant increase in the response of the right amygdala (Figure 3 ). Additional responses during both sessions were identified in the bilateral posterior fusiform gyri, inferior parietal lobules and frontal eye fields, a distributed neural network involved in perceptual face processing (Haxby et al. 2002) . However, DEX did not potentiate the responses of these other regions.
RESULTS
There was no difference in performance for either task between PBO and DEX sessions (accuracy: F 1,44 ϭ 0.83, p ϭ .37, and reaction time: F 1,40 ϭ 0.38, p ϭ .54). Although subjects did report increased vigor and energy, DEX was not associated with heightened levels of anxiety or fear as indexed by either the Profile of Mood Scales or Spielberger anxiety scales. The absence of anxiogenic effects in the current study are not surprising given the relatively low physiological doses of DEX administered and the controlled environment. While measurable levels of DEX were detected in all subjects, ranging from 46 to 71 ng/ml (mean 57.3 ng/ml), previous work has illustrated that symptoms of intense anxiety and panic require persistent administration of amphetamine exceeding 150 mg/day (Ellinwood et al. 1973 ).
Figure 1. Experimental paradigm. (A)
During the emotion task, subjects viewed a trio of faces and had to select one of two faces (bottom) that expressed the same emotion as the target face (top). The identity of all three faces was always different and an equal number of male and female faces was presented. (B) During the sensorimotor control, the subjects viewed a trio of geometric shapes and had to select one of two shapes (bottom) identical to the target shape (top).
DISCUSSION
The potentiation of the amygdala response by DEX suggests that this structure may be involved in mediating the anxiogenic effects of amphetamine and perhaps other catecholaminergic stimulants. The regional specificity of this potentiation further implicates the amygdala as a critical brain structure for the extraction of affective information from environmental stimuli. The laterality of the potentiated amygdala response may reflect specialization of right hemisphere structures for the perceptual processing of emotional information, especially that of a visual nature. However, such hemispheric laterality may also reflect methodological phenomenon such as insufficient BOLD sensitivity and signal-to-noise ratio, especially in regions vulnerable to susceptibility artifacts such as the amygdala (LaBar et al. 2001) . The consistency and nature of this observed laterality needs to be further explored in future studies.
Given the previously described task-and region-specific effects of DEX on brain regions subserving complex behavior (Mattay et al. 1996) , the absence of DEXpotentiated responses in other brain regions, such as the posterior fusiform gyri, suggests that these regions, unlike the amygdala, may not be critical for the processing of the emotional content of stimuli specifically. Rather, they are likely involved in general perceptual processes such as recognizing faces from non-face objects (Haxby et al. 2002; Kanwisher et al. 1997) . In addition, the absence of a DEX-potentiated response in these other regions suggests that the observed specific potentiation of the amygdala does not simply reflect global effects of DEX on either the neurovascular response or attentional phenomenon.
While DEX is generally regarded as a nonspecific monoaminergic agonist, there is considerable evidence suggesting that its primary mode of action is via DA neurotransmission. For example, DA D1 receptor and DA transporter knockout mice are insensitive to the psychostimulant effects of both cocaine and amphetamine (Zhang and Xu 2001) , and behavioral sensitiza- Table 1 for complete Talairach coordinates and voxel-level statistics. tion to amphetamine is primarily mediated through mesocorticolimbic dopamine projections (Pierce and Kalivas 1997) . Furthermore, additional studies have illustrated the importance of DA in the response of the amygdala to stress (Inglis and Moghaddam 1999) as well as in conditioned fear behavior (Guarraci et al. 1999; Nader and LeDoux 1999) . However, the effects of DEX may also be mediated by serotonergic and noradrenergic systems, both of which have been implicated in emotional reactivity and behavior (Goldstein et al. 1996) . Future work using specific monoaminergic agonists is needed to clarify the contributions of each system to amygdala activity.
Our results provide the first in vivo demonstration in human subjects of a powerful potentiation of the amygdala by DEX and provide insight to the underlying neural substrate of some of the emotion enhancing effects of amphetamine as well as neuropharmacological modulation of amygdala activity. The potentiated amygdala response we report may reflect DA gating of amygdala inputs and subsequent amygdala neural firing. Recently, Rosenkranz and Grace have shown that DA potentiates the response of the amygdala by attenuating the effect of inhibitory input from the prefrontal cortex and augmenting the effect of excitatory input from sensory cortices (Rosenkranz and Grace 2001) . Consistent with their findings, our fMRI data may reflect such DA mediated augmentation of excitatory sensory input to the amygdala and concurrent attenuation of inhibitory prefrontal input. It is important to note that prefrontal inhibition of the amygdala has been described in human studies (Hariri et al. 2000) and may be another critical element of emotional regulation. Furthermore, our finding that amphetamine did not change responses in other brain regions supports the interpretation that its effects on the amygdala reflect local information processing at the level of the amygdala itself.
